An Evidence-Based Formulation (EBF) is a differentiated drug that has been reformulated to offer additional patient benefit. EBF's are often fixed-dose combinations of active drugs or new formulations with different pharmacokinetic properties, new routes of delivery, or improved safety profiles. EBF's are also referred to as Value Added Formulations, or Incrementally Modified Drugs.
One of the world's leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit
About GSK in
is home to GSK's Regional Headquarters (Emerging Markets &
), an R&D facility (Biopolis), two global manufacturing and supply sites (Jurong & Quality Road), a Stiefel manufacturing facility, and a state-of-the-art vaccines plant (Tuas).
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven
. A*STAR oversees 14 biomedical sciences and physical sciences and engineering research institutes, and six consortia & centres, located in Biopolis and Fusionopolis as well as their immediate vicinity.
key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, and with other local and international partners.
For more information about A*STAR, please visit
About the Institute of Chemical and Engineering Sciences (ICES)
Institute of Chemical and Engineering Sciences (ICES) is a member of the Agency for Science, Technology and Research (A*STAR). Established in 2002, its mission is to carry out world class scientific research, to develop novel technology and to nurture creative scientists and engineers to support economic growth in
and to make a positive difference to society. The research area covers chemistry and chemical engineering science, combined with advanced analytical characterisation and measurement to develop state of the art technology for the petrochemical, general chemical, fine chemical and pharmaceutical industries. For more information, visit
Growth in emerging markets especially
will account for nearly 40% of the global pharmaceutical market by 2016. - Roland Berger Strategy Consultants, "Global Pharmaceutical Industry Is In A Strategic Crisis - Business Models Must Be Adjusted",
For media enquiries, please contact: